Company intelligence / Profile preview
coeruleus
Rosh Pinna, Israelcoeruleus.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
coeruleus is developing a high-concentration sublingual spray formulation of flumazenil ("flumup") for rapid reversal of lingering sedative effects after use of hypnotic-sedative sleep medications. The company targets the large market for sleep disorder treatments and aims to address unmet needs related to next-day impairment from common prescription sleeping pills. No published clinical results are available as yet.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculeSublingual spray formulation
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
COS Israel
Beyond the preview
Go deeper on coeruleus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coeruleus.